Multiple-organ failure in patients with severe coronavirus disease (COVID-19)

Authors

  • I.A. Kuchynska Shupyk National University of Public Health of Ukraine, Kyiv, Ukraine; Universal Clinic “Oberig”, Kyiv, Ukraine
  • B.O. Savchenko Universal Clinic “Oberig”, Kyiv, Ukraine; Bogomolets National Medical University, Kyiv, Ukraine
  • A.H. Andriukhov Universal Clinic “Oberig”, Kyiv, Ukraine
  • A.M. Ivanchenko Universal Clinic “Oberig”, Kyiv, Ukraine
  • N.V. Astashkina Universal Clinic “Oberig”, Kyiv, Ukraine
  • Ye.O. Hulevatyi Universal Clinic “Oberig”, Kyiv, Ukraine
  • U.L. Kashchii Universal Clinic “Oberig”, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0586.17.2.2021.230632

Keywords:

COVID-19, SARS-CoV-2, multiple-organ dysfunctions, multiple-organ failure, cytokine imbalance, intensive care, review

Abstract

The article analyzes the mechanisms of the development and clinical manifestations of multi-organ dysfunction and multi-organ failure syndrome, which often accompany the severe COVID-19. Moreover, since multiple organ dysfunction during severe COVID-19 may be caused by a cytokine storm resulting from elevated inflammatory mediators, endothelial dysfunction, coagulation disorders, and inflammatory cell infiltration, further studies are needed to determine the exact mechanisms of pathogenesis. Since the involvement of multiple organs in the pathological process of the disease during coronavirus infection is an important and complex medical, mental, tactical, physical, emotional, and economic task for both clinicians and patients and their families, increasing knowledge of the pathological process can help improve outcomes and reduce morbidity and mortality. The review includes some results of our own experience in the treatment of severe cases of coronavirus disease.

References

Liu D.X., Liang J.Q., Fung T.S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1. Reference Module in Life Sciences. 2020a. B978-970-912-809633-809638.10.1016/B978-0-12-809633-8.21501-X.

Baud D., Qi X., Nielsen-Saines K., Musso D., Pomar L., Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect. Dis. 2020 Jul. 20(7). 773.

Lei F., Liu Y.M., Zhou F., Qin J.J., Zhang P., Zhu L. et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020 Aug. 72(2). 389-398.

Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020, Aug 1. 116(10). 1666-1687.

Cheng Y., Luo R., Wang K., Zhang M. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020 May. 97(5). 829-838.

Mukherjee A., Ahmad M., Frenia D. A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine. Cureus. 2020, Mar 30. 12(3). e7473.

Yi Y., Lagniton P.N.P., Ye S., Li E., Xu R.H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int. J. Biol. Sci. 2020. 16(10). 1753-1766.

Chen J., Qi T., Liu L., Ling Y., Qian Z. Clinical progression of patients with COVID-19 in Shanghai, China. J. Infect. 2020 May. 80(5). 1-6.

Wu C., Chen X., Cai Y., Xia J. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020, Jul 1. 180(7). 934-943.

Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004 Jun. 203(2). 631-637.

Pyrc K., Berkhout B., van der Hoek. The novel human coronaviruses NL63 and HKU1. J. Virol. 2007 Apr. 81(7). 3051-3057.

Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005, Jul 7. 436(7047). 112-116.

Yamamoto S., Yancey P.G., Zuo Y., Ma L.J. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011 Dec. 31(12). 2856-2864.

Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017 Jul. 39(5). 529-539.

Lei F., Liu Y.M., Zhou F., Qin J.J., Zhang P. et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020 Aug. 72(2). 389-398.

Gao T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. 2020.

Ciceri F., Beretta L., Scandroglio A.M., Colombo S. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit. Care Resusc. 2020, Apr 15. 22(2). 95-97.

Wölfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May.

Yang J., Zheng Y., Gou X. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis [published online ahead of print, 2020 Mar 12]. Int. J. Infect. Dis. 2020. doi: 10.1016/j.ijid.2020.03.017. S1201-9712(20)30136-3.

Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020. doi: 10.1001/jama.2020.1585.

Khashkhusha T.R., Chan J.S.K., Harky A. ACE inhibitors and COVID-19: We don’t know yet. J. Card. Surg. 2020. doi: 10.1111/jocs.14582.

Tan L., Wang Q., Zhang D. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sign. Transduct. Target. Ther. 2020. 5(1). 33.

Mina A., van Besien K., Platanias L.C. Hematological manifestations of COVID-19. Leukemia Lymphoma. 2020. DOI: 10.1080/10428194.2020.1788017 [Ref list].

Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin. Chim. Acta. 2020 Jul. 506. 145-148.

Terpos E. et al. Hematological findings and complications of COVID-19 American journal of hematology [Ref list]. 2020.

COVID-19 update: COVID-19-associated coagulopathy. Becker RCJ Thromb. Thrombolysis. 2020 Jul. 50(1). 54-67.

Cals J.W., Schot M.J., de Jong S.A., Dinant G.J., Hopstaken R.M. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann. Fam. Med. 2010 Mar-Apr. 8(2). 124-133.

Tan T., Khoo B., Mills E.G., Phylactou M., Patel B. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol. 2020 Aug. 8(8). 659-660.

Wu M.Y., Yao L., Wang Y., Zhu X.Y., Wang X.F., Tang P.J., Chen C. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir. Res. 2020, Jul 6. 21(1). 171.

Arentz M., Yim E., Klaff L. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State [published online ahead of print, 2020 Mar 19]. JAMA. 2020. 323(16). 1612-1614.

Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020, Mar 28. 395(10229). 1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020. 395. 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

Cheng Y., Luo R., Wang K. Kidney disease is associated with in-hospital death of patients with COVID-19 [published online ahead of print, 2020 Mar 20]. Kidney Int. 2020. doi: 10.1016/j.kint.2020.03.005. S0085-2538(20)30255-6.

Naicker S., Yang C.W., Hwang S.J., Liu B.C., Chen J.H., Jha V. The Novel Coronavirus 2019 epidemic and kidneys [published online ahead of print, 2020 Mar 7]. Kidney Int. 2020. doi: 10.1016/j.kint.2020.03.001.

Li Z., Wu M., Yao J. Caution on kidney dysfunctions of ­COVID-19 patients. medRxiv. 2020. doi: 10.1101/2020.02.08.20021212 [Cross Ref] [Google Scholar] [Ref list].

Su H., Yang M., Wan C., Yi L.X., Tang F., Zhu H.Y. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 Jul. 98(1). 219-227.

Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020. 5. 428-430. doi: 10.1016/S2468-1253(20)30057-1.

Beeching N., Fowler R. Coronavirus disease 2019 (COVID-19). BMJ Best Practice. 2020. https://bestpractice.bmj.com/topics/en-gb/3000168/emergingtxs. Published Updated: Apr 2020. Accessed: April 11 2020.

Mao L., Wang M.D., Chen S.H. Neurological manifestation of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020. doi: 10.1101/2020.02.22.20026500 [CrossRef] [Google Scholar] [Ref list].

Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients [published online ahead of print, 2020 Feb 27]. J. Med. Virol. 2020. doi: 10.1002/jmv.25728 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list].

NHS. Clinical guide for the optimal use of oxygen therapy during the coronavirus pandemic. Specialty guides for patient management during the coronavirus (COVID-19) pandemic. Published2020. Available at: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0256-specialty-guide-oxygen-therapy-and-coronavirus-9-april-2020.pdf [Accessed April 13, 2020]. [Ref list].

Guérin C., Reignier J., Richard J.C. Prone positioning in severe acute respiratory distress syndrome. N. Engl. J. Med. 2013. 368. 2159-2168. doi: 10.1056/NEJMoa1214103. [PubMed] [CrossRef] [Google Scholar] [Ref list].

Halushko O., Loskutov O., Kuchynska I., Synytsyn M., Boliuk M. The main causes of the complicated course of COVID-19 in diabetic patients (review). Georgian Medical News. 2020. № 10(307). 114-120.

Rhodes A., Evans L.E., Alhazzani W. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017. 43. 304-377. doi: 10.1007/s00134-017-4683-6 [PubMed] [CrossRef] [Google Scholar] [Ref list].

Published

2021-05-24

Issue

Section

Scientific Review